Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.


(e)

Executive Officer Cash Bonuses

On February 3, 2021, the Compensation Committee of the Board of Directors of BioAtla, Inc. (the "Company"), approved the following cash bonuses for 2020 for the Company's principal financial officer and named executive officers, other than the Chief Executive Officer, based on the Company's achievement of certain clinical development milestones and business objectives in 2020. Each executive officer will receive 110% of their target bonus as set forth below.





Name and Position                                                    2020 Cash Bonus
Richard Waldron
Chief Financial Officer                                             $         184,321
Scott Smith
President & Director                                                $         291,005

Carolyn Anderson Short Executive Vice President and Chief of Intellectual Property and Strategy, Co-founder, and Assistant Secretary

                   $         303,293

On February 4, 2021, the Compensation Committee recommended, and the Company's Board of Directors approved, a cash bonus of $418,594 for 2020 for Jay Short, the Company's Chief Executive Officer, based on the Company's achievement of certain clinical development milestones and business objectives in fiscal year 2020. Dr. Short's bonus reflects 110% of his target bonus.

2021 Corporate Bonus Plan

On February 3, 2021, the Compensation Committee approved and adopted the 2021 Corporate Bonus Plan (the "Bonus Plan") and corporate performance goals under the Bonus Plan applicable for 2021. The Company's Chief Executive Officer, Chief Financial Officer, and each of the Company's named executive officers is a participant in the Bonus Plan and subject to the 2021 corporate performance goals.

The Bonus Plan provides the executive officers with the opportunity to earn an annual cash bonus that is paid based on the achievement of corporate performance goals. Each of these performance goals receives a different weight when the bonus attainment is calculated. The corporate performance goals consist of certain clinical development milestones (55% weight), research and development goals (25% weight), and strategic objectives (20% weight). The amount of annual bonus earned depends on whether the Company achieves the performance level for the applicable corporate performance goal. Each of the performance goals is measured independently of the other. Payment of cash bonuses will be subject to attaining 50% threshold performance of the weighted combination of the corporate performance goals overall. Actual payouts may range from 50% to 125% of target, based on performance.



The target annual bonus amount for each participating executive officer is set
at a percentage of the named executive officer's annual base salary as set forth
in the table below:



Name and Position                                         Percentage Target of Base Salary
Jay Short
Chief Executive Officer                                                                  60 %
Richard Waldron
Chief Financial Officer                                                                  40 %
Scott Smith
President & Director                                                                     50 %
Carolyn Anderson Short
Executive Vice President and Chief of
Intellectual Property and Strategy,
Co-founder, and Assistant Secretary                                                      50 %

The annual cash bonus for each executive officer will be equal to (1) the applicable target annual bonus amount multiplied by (2) the percentage achievement applicable to the weighted combination of those goals identified above as achieved by the Company in 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses